These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 23129824)

  • 21. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders.
    Ghobrial IM; Habermann TM; Maurer MJ; Geyer SM; Ristow KM; Larson TS; Walker RC; Ansell SM; Macon WR; Gores GG; Stegall MD; McGregor CG
    J Clin Oncol; 2005 Oct; 23(30):7574-82. PubMed ID: 16186599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA; Hamilton-Dutoit S; Bendtzen K
    Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management and outcome of liver recipients with post-transplant lymphoproliferative disease.
    Glez-Chamorro A; Jimenez C; Moreno-Glez E; Glez-Pinto I; Loinaz C; Gomez R; Garcia I; Alonso O; Palma F; Grande C
    Hepatogastroenterology; 2000; 47(31):211-9. PubMed ID: 10690611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment.
    Garcia VD; Bonamigo Filho JL; Neumann J; Fogliatto L; Geiger AM; Garcia CD; Barros V; Keitel E; Bittar AE; Ferrera des Santos A; Roithmann S
    Transpl Int; 2003 Mar; 16(3):202-6. PubMed ID: 12664217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
    Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
    Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Posttransplant lymphoproliferative disorders after liver transplantation: analysis of early and late cases in a 255 patient series.
    Avolio AW; Agnes S; Barbarino R; Magalini SC; Frongillo F; Pagano L; Larocca LM; Pompili M; Caira M; Sollazzi L; Castagneto M
    Transplant Proc; 2007; 39(6):1956-60. PubMed ID: 17692665
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation.
    Lee JJ; Lam MS; Rosenberg A
    Ann Pharmacother; 2007 Oct; 41(10):1648-59. PubMed ID: 17848421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplantation lymphoproliferative disorder in pediatric kidney-transplant recipients - a national study.
    Cleper R; Ben Shalom E; Landau D; Weissman I; Krause I; Konen O; Rahamimov R; Mor E; Bar-Nathan N; Frishberg Y; Davidovits M
    Pediatr Transplant; 2012 Sep; 16(6):619-26. PubMed ID: 22708682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab induction therapy in highly sensitized kidney transplant recipients.
    Yin H; Wan H; Hu XP; Li XB; Wang W; Liu H; Ren L; Zhang XD
    Chin Med J (Engl); 2011 Jul; 124(13):1928-32. PubMed ID: 22088448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan.
    Ishihara H; Shimizu T; Unagami K; Hirai T; Toki D; Omoto K; Okumi M; Imai Y; Ishida H; Tanabe K
    Ther Apher Dial; 2016 Apr; 20(2):165-73. PubMed ID: 26948427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.
    Evens AM; David KA; Helenowski I; Nelson B; Kaufman D; Kircher SM; Gimelfarb A; Hattersley E; Mauro LA; Jovanovic B; Chadburn A; Stiff P; Winter JN; Mehta J; Van Besien K; Gregory S; Gordon LI; Shammo JM; Smith SE; Smith SM
    J Clin Oncol; 2010 Feb; 28(6):1038-46. PubMed ID: 20085936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of early and late PTLD development in pediatric solid organ transplant recipients.
    Schober T; Framke T; Kreipe H; Schulz TF; Großhennig A; Hussein K; Baumann U; Pape L; Schubert S; Wingen AM; Jack T; Koch A; Klein C; Maecker-Kolhoff B
    Transplantation; 2013 Jan; 95(1):240-6. PubMed ID: 23222898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-transplant lymphoproliferative disorders in liver transplanted patients: a single-centre experience.
    Marino D; Burra P; Boccagni P; Calabrese F; Canova F; Trentin C; Boso C; Soldà C; Angeli P; Aversa SM
    Anticancer Res; 2010 Jun; 30(6):2383-91. PubMed ID: 20651397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients.
    Capello D; Rasi S; Oreste P; Veronese S; Cerri M; Ravelli E; Rossi D; Minola E; Colosimo A; Gambacorta M; Muti G; Morra E; Gaidano G
    J Pathol; 2009 Aug; 218(4):478-86. PubMed ID: 19391128
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD20 antigen expression by lymphoproliferative disorders after kidney transplant is independently associated with a poor outcome: PTLD.Int survey.
    Khedmat H; Taheri S
    Exp Clin Transplant; 2012 Aug; 10(4):325-31. PubMed ID: 22758374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA; Hamilton-Dutoit S
    Transplantation; 2003 Sep; 76(6):984-8. PubMed ID: 14508366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. B-cell posttransplant lymphoproliferative disorders in heart and/or lungs recipients: clinical and molecular-histogenetic study of 17 cases from a single institution.
    Lucioni M; Capello D; Riboni R; Ippoliti G; Campana C; Bandiera L; Arcaini L; Rossi D; Cerri M; Dionigi P; Lazzarino M; Magrini U; Viganò M; Gaidano G; Paulli M
    Transplantation; 2006 Oct; 82(8):1013-23. PubMed ID: 17060848
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation.
    Maecker B; Jack T; Zimmermann M; Abdul-Khaliq H; Burdelski M; Fuchs A; Hoyer P; Koepf S; Kraemer U; Laube GF; Müller-Wiefel DE; Netz H; Pohl M; Toenshoff B; Wagner HJ; Wallot M; Welte K; Melter M; Offner G; Klein C
    J Clin Oncol; 2007 Nov; 25(31):4902-8. PubMed ID: 17971586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.